Dianthus Therapeutics (DNTH) Cash & Equivalents (2017 - 2025)

Dianthus Therapeutics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $50.2 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 128.96% year-over-year to $50.2 million; the TTM figure through Dec 2025 stood at $50.2 million (up 128.96% YoY), while the FY2025 annual figure was $50.2 million, up 128.96% from the prior year.
• Cash & Equivalents was $50.2 million for Q4 2025 at Dianthus Therapeutics, down from $56.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $329.7 million in Q1 2024 to a low of $10.1 million in Q1 2025.
• Historically, Cash & Equivalents has averaged $92.7 million across 5 years, with a median of $52.5 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 1320.49% in 2024, then tumbled 96.93% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $131.6 million in 2021, then tumbled by 88.33% to $15.4 million in 2022, then soared by 761.21% to $132.3 million in 2023, then tumbled by 83.42% to $21.9 million in 2024, then surged by 128.96% to $50.2 million in 2025.
• The last three Cash & Equivalents figures came in at $50.2 million (Q4 2025), $56.0 million (Q3 2025), and $12.0 million (Q2 2025), per Business Quant data.